Skip to content
All resources

Testing, quality and handling

Peptide Degradation: Oxidation, Deamidation, Hydrolysis and Aggregation Explained

NB

By

· 10 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 9 sections
  1. What are the main ways a peptide degrades?
  2. Which residues oxidise, and what drives it?
  3. What is deamidation, and why is Asn-Gly the hot spot?
  4. How does aspartate isomerisation differ from deamidation?
  5. When does the peptide backbone hydrolyse?
  6. What is diketopiperazine formation?
  7. What drives aggregation, and how is it detected?
  8. How do you tell which pathway a peptide is following?
  9. Frequently asked questions

Peptide degradation is the chemical or physical change of a peptide into something other than its intended structure. The main chemical routes are oxidation of methionine, cysteine and tryptophan; deamidation of asparagine, fastest before glycine; isomerisation of aspartate to isoaspartate; hydrolysis of the backbone; and diketopiperazine formation at the amino terminus. The main physical route is aggregation. Each is driven by particular residues and conditions, water, pH, temperature, oxygen, metals and light, and each needs a specific analytical method to detect, because several leave the peptide's mass unchanged.

A chain of glass beads with several beads breaking away at one end
Illustration, not an exact structure: degradation changes a chain one bond at a time.

This article is the general reference for those routes. How they apply to particular sequences is worked through for MOTS-c in solution, BPC-157 in solution and the dried state in lyophilised peptides. Neither MOTS-c nor BPC-157 is an approved medicine anywhere; both are research compounds whose literature is preclinical or very limited in humans.

What are the main ways a peptide degrades?

The classic division, set out in Manning, Patel and Borchardt's review, separates chemical instability, which makes or breaks covalent bonds, from physical instability, which changes structure or association without doing so. They list proteolysis, deamidation, oxidation, racemisation and beta-elimination on the chemical side, and aggregation, precipitation, denaturation and adsorption to surfaces on the physical side (PMID 2687836). The later update by Manning and colleagues extends the same framework (PMID 20143256).

PathwayResidues or motif at riskMain driversMass changeMain detection methods
OxidationMet, Cys, Trp, His, TyrDissolved oxygen, peroxides, trace metals, lightAbout +16 Da per oxygen (Met sulfoxide); Cys forms disulfidesReverse-phase HPLC (oxidised forms usually elute earlier), LC-MS
DeamidationAsn, especially Asn-Gly; Gln more slowlyNeutral to basic pH, temperature, buffer species, moistureAbout +1 DaLC-MS with good mass accuracy, ion-exchange chromatography, resolving HPLC
Aspartate isomerisationAsp, especially Asp-Gly and Asp followed by small residuespH, temperatureNoneResolving HPLC, enzymatic isoaspartate assays, MS fragmentation
Backbone hydrolysisAsp-X bonds, especially Asp-Pro; any bond at extreme pHLow pH, temperature, waterFragmentsHPLC, LC-MS of fragments
Diketopiperazine formationN-terminal dipeptide, especially X-ProFree N-terminal amine, pH near or above neutral, temperatureLoss of the first two residuesLC-MS, HPLC
AggregationHydrophobic, amyloidogenic or amphipathic sequencesConcentration, interfaces, agitation, pH near pI, freeze-thawNone for non-covalent aggregatesSize-exclusion chromatography, light scattering, turbidity, dye-binding assays

Which residues oxidise, and what drives it?

Li, Schöneich and Borchardt list methionine, cysteine, histidine, tryptophan and tyrosine as the residues most susceptible, because of their reactivity with reactive oxygen species. Oxidation can be induced by contaminating oxidants, catalysed by transition metal ions, or induced by light, and is influenced by pH, temperature and buffer (PMID 18623513).

They draw a distinction that matters in practice. Oxidation by oxidants dispersed in solution is non-site-specific and can be inhibited by antioxidants. Metal-catalysed oxidation is site-specific, occurring where a metal binds the peptide, and there the addition of some antioxidants can accelerate it; chelating agents are the alternative (PMID 18623513). A blanket rule such as "add an antioxidant" can therefore make one kind of oxidation worse.

Methionine to methionine sulfoxide adds about 16 Da and usually makes the peptide slightly more polar, so it elutes earlier in reverse-phase HPLC and is readily seen by LC-MS. Cysteine can form intermolecular disulfides (dimers) or further oxidised species. Tryptophan oxidation yields several products of different masses. A sequence with two methionines and a tryptophan, like MOTS-c, has several oxidation sites, which is why oxidation dominates that compound's stability article.

What is deamidation, and why is Asn-Gly the hot spot?

Asparagine's side-chain amide can be lost through attack by the backbone nitrogen of the following residue, forming a five-membered succinimide ring that then hydrolyses to a mixture of aspartate and isoaspartate. The following residue controls the rate, because a small residue lets the backbone reach.

Geiger and Clarke measured this in the model hexapeptide Val-Tyr-Pro-Asn-Gly-Ala. At 37 °C and pH 7.4 it deamidated with a half-life of only 1.4 days, through a succinimide that then hydrolysed or racemised. Replacing the glycine after asparagine with bulky leucine or proline slowed degradation 33- to 50-fold, and replacing the asparagine with aspartate slowed succinimide formation 34-fold (PMID 3805008). Those are figures for a model peptide under physiological conditions, not a shelf life for any product, but they show how much the neighbouring residue matters.

Conditions change the mechanism as well as the rate. Patel and Borchardt found that the same hexapeptide deamidated exclusively through the cyclic imide between pH 5 and 12, giving both aspartate and isoaspartate products with buffer catalysis between pH 7 and 11, whereas at acidic pH the amide side chain was hydrolysed directly to give only the aspartate product (PMID 2395797). Robinson and Robinson later measured deamidation rates for 306 asparagine sequences in model peptides, a dataset that underlies sequence-based predictions (PMID 11158575).

Deamidation adds about 1 Da. That is easy to miss at low mass resolution and easy to see with good mass accuracy, and the extra negative charge also shifts the peptide in ion-exchange chromatography.

How does aspartate isomerisation differ from deamidation?

Aspartate forms the same succinimide intermediate, more slowly than asparagine, by losing water instead of ammonia, and the ring reopens to aspartate or isoaspartate and can racemise to the D-form (PMID 3805008). The net change in mass is zero. Mass spectrometry cannot see it by mass alone, and isoaspartyl forms may elute close to the main peak. This is the degradation most likely to pass an analysis that has not been shown to resolve it, which is why it receives its own section in the BPC-157 stability article. Detection relies on a validated, resolving HPLC method, enzymatic assays that recognise isoaspartate, or MS fragmentation that distinguishes the isomers. The same chemistry occurs during synthesis as aspartimide formation, described in solid-phase peptide synthesis explained.

When does the peptide backbone hydrolyse?

Peptide bonds are kinetically stable at neutral pH but cleave under strongly acidic or basic conditions and at higher temperature. Bonds following aspartate are especially labile in acid, because the side-chain carboxyl assists the cleavage, and the Asp-Pro bond is the classic weak point. The products are two fragments whose masses add up to the parent plus water, so LC-MS identifies them readily, and HPLC usually separates them. Hydrolysis needs water, which is the main reason drying slows it so much.

What is diketopiperazine formation?

When the amino terminus is a free amine, it can attack the carbonyl of the second peptide bond, releasing the first two residues as a cyclic dipeptide, a diketopiperazine, and leaving a peptide two residues shorter. Goolcharran and Borchardt studied it in model peptides and found the rate depended on the ionisation of the N-terminal amine, with the unprotonated form more reactive, a kinetically determined pKa of 6.1, and a significant effect of the residue preceding proline on the rate at pH 7.0 (PMID 9523979). Sequences with proline in the second position are the most prone. Acetylating or otherwise blocking the N-terminus removes the pathway. Detection is by the mass of the truncated product in LC-MS.

What drives aggregation, and how is it detected?

Aggregation is association of peptide molecules, reversible or not, non-covalent or crosslinked, from small oligomers to visible particles and amyloid fibrils. It is promoted by high concentration, by pH near the isoelectric point where net charge is lowest, by hydrophobic and amphipathic sequences, and by interfaces: air-liquid, ice-liquid and container surfaces. Frokjaer and Otzen place aggregation and misfolding during storage among the central stability problems for protein and peptide drugs and point to the growth of fibrillation research as a route to better tests (PMID 15803194). How agitation acts mainly through the air-liquid interface is covered in does shaking damage peptides, and an amylin-analogue example in cagrilintide cloudiness and aggregation.

Reverse-phase HPLC is poor at seeing non-covalent aggregates, because its organic solvent and acid often dissociate them into monomer, which then integrates as the main peak. Size-exclusion chromatography under native conditions, dynamic light scattering, turbidity, sub-visible particle counting and dye-binding assays such as thioflavin T for amyloid are the appropriate tools. Loss of peptide by adsorption to surfaces, which removes material without changing what remains, needs a content measurement rather than a purity measurement, as discussed in peptide net content vs purity.

How do you tell which pathway a peptide is following?

By pairing a separation with a mass for each new peak. A peak about 16 Da heavier points to oxidation; about 1 Da heavier to deamidation; two residues lighter to diketopiperazine formation; a pair of fragments to hydrolysis. A peak with the parent's exact mass is an isomer, isoaspartyl, racemised or a conformer, and needs further work. Loss of total peptide with no new peaks suggests aggregation or adsorption. That is why HPLC vs LC-MS peptide testing argues that coupling the two is a different quality of evidence from running either alone, and why a stability-indicating method has to be shown to separate each relevant degradation product from the parent.

A single certificate, as what a certificate of analysis establishes explains, describes one lot at one time. It cannot tell you which of these routes will matter later. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Which peptide degradation pathway is the most common? It depends entirely on the sequence and conditions. A peptide with methionine or tryptophan exposed to oxygen and metals will usually oxidise first; one with an Asn-Gly motif at neutral pH will usually deamidate first; a peptide lacking both, like BPC-157, shifts attention to aspartate isomerisation and aggregation. The sequence is the first thing to read.

Why can a degraded peptide still show high HPLC purity? Because several products co-elute with the parent or are hidden by the method. Isoaspartyl and racemised forms have the same mass and often similar retention; non-covalent aggregates may dissociate on the column; adsorbed peptide is simply absent. Only a method validated to resolve each product, plus a content measurement, rules these out.

Does freezing stop degradation? It slows chemical reactions greatly, but freezing concentrates solutes, can shift pH as buffer components crystallise, and creates an ice-liquid interface where aggregation can begin. Repeated freeze-thaw cycles are a stress in their own right. In the dried state, residual water and storage temperature relative to the glass transition govern how slowly reactions continue.

Is deamidation the same as aspartate isomerisation? They share an intermediate, a succinimide ring, but start from different residues. Deamidation begins at asparagine, loses ammonia and adds about 1 Da. Isomerisation begins at aspartate, loses then regains water, and leaves the mass unchanged. Both can produce isoaspartate and D-aspartate, and both are fastest when the next residue is small.

Selected Research References

  1. Manning MC, Patel K, Borchardt RT. Stability of Protein Pharmaceuticals. Pharmaceutical Research. 1989;6(11):903-918. pubmed.ncbi.nlm.nih.gov/2687836
  2. Manning MC, Chou DK, Murphy BM, et al. Stability of Protein Pharmaceuticals: An Update. Pharmaceutical Research. 2010;27(4):544-575. pubmed.ncbi.nlm.nih.gov/20143256
  3. Li S, Schöneich C, Borchardt RT. Chemical Instability of Protein Pharmaceuticals: Mechanisms of Oxidation and Strategies for Stabilization. Biotechnology and Bioengineering. 1995;48(5):490-500. pubmed.ncbi.nlm.nih.gov/18623513
  4. Geiger T, Clarke S. Deamidation, Isomerization, and Racemization at Asparaginyl and Aspartyl Residues in Peptides: Succinimide-Linked Reactions That Contribute to Protein Degradation. Journal of Biological Chemistry. 1987;262(2):785-794. pubmed.ncbi.nlm.nih.gov/3805008
  5. Patel K, Borchardt RT. Chemical Pathways of Peptide Degradation. II. Kinetics of Deamidation of an Asparaginyl Residue in a Model Hexapeptide. Pharmaceutical Research. 1990;7(7):703-711. pubmed.ncbi.nlm.nih.gov/2395797
  6. Robinson NE, Robinson AB. Molecular Clocks. Proceedings of the National Academy of Sciences. 2001;98(3):944-949. pubmed.ncbi.nlm.nih.gov/11158575
  7. Goolcharran C, Borchardt RT. Kinetics of Diketopiperazine Formation Using Model Peptides. Journal of Pharmaceutical Sciences. 1998;87(3):283-288. pubmed.ncbi.nlm.nih.gov/9523979
  8. Frokjaer S, Otzen DE. Protein Drug Stability: A Formulation Challenge. Nature Reviews Drug Discovery. 2005;4(4):298-306. pubmed.ncbi.nlm.nih.gov/15803194

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.